Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
Gain Therapeutics reported positive interim data from its Phase 1b trial of rexaceract in Parkinson's disease, including an 81% reduction in the GluSph biomarker and sustained clinical benefit through 150 days, paving the way for a Phase 2 study expected to start in Q3 2026. The company holds $16.5 million in cash, which it estimates will fund operations into the second quarter of 2027, while it continues to leverage an ATM facility and explore partnerships. Management announced the promotion of Joanne Taylor to CSO and Terenzio Ignoni to COO, while noting that Dr.
Key figures
- Cash
- $16.5M
- Cash runway
- Q2 2027
- Glusph reduction avg
- 81%
- Mds updrs improvement points
- 4.8
- Phase1b participants day 150
- 16
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.